Who founded Inovio?
Who founded Inovio?
David B. Weiner
Inovio Pharmaceuticals Inc (NASDAQ:INO) Its product pipeline include VGX-3100, INO-3107, INO-5410, INO-4800, and PENNVAX-GP. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.
What is inovio known for?
Inovio Pharmaceuticals formerly known as Electrofect founded in 1999 renamed to Inovio in October 2001 is an American biotechnology company focused on the discovery, development, and commercialization of synthetic DNA products for treating cancers and infectious diseases….Inovio Pharmaceuticals.
| Type | Public |
|---|---|
| Website | inovio.com |
What happened to Inovio Pharmaceuticals?
The Food and Drug Administration reversed a decision that barred Inovio Pharmaceuticals (INO) from testing its Covid vaccine in the U.S., and INO stock popped. The illness is caused by a coronavirus. It’s more fatal than Covid, though far less common.
Who owns Inovio Pharmaceuticals?
Top 10 Owners of Inovio Pharmaceuticals Inc
| Stockholder | Stake | Total value ($) |
|---|---|---|
| The Vanguard Group, Inc. | 5.04% | 76,699,264 |
| JPMorgan Asset Management (UK) Lt… | 1.89% | 28,715,455 |
| D. E. Shaw & Co. LP | 1.80% | 27,460,285 |
| Wasatch Advisors, Inc. | 1.71% | 25,974,485 |
When was Inovio started?
1999
Inovio Pharmaceuticals, Inc./Founded
What is Cellectra?
PROPRIETARY SMART DEVICES (CELLECTRA®) The CELLECTRA device uses a brief electrical pulse to reversibly open small pores in the cell to allow the plasmids to enter, overcoming a key limitation of other DNA and other nucleic acid approaches, such as mRNA.
What is Ino Pharmaceutical?
INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to help protect people from infectious diseases and treat cancer and HPV-associated diseases, today announced the company is rapidly moving to evaluate its COVID-19 DNA vaccine candidates INO-4800 and INO-4802 …
Will ino go up?
Will Inovio Pharmaceuticals stock price grow / rise / go up? Yes. The INO stock price can go up from 5.990 USD to 8.192 USD in one year.
Who owns inuvo stock?
Top 10 Owners of Inuvo Inc
| Stockholder | Stake | Shares owned |
|---|---|---|
| Ingalls & Snyder LLC | 4.73% | 5,621,023 |
| Herald Investment Management Ltd. | 4.46% | 5,292,857 |
| Perkins Capital Management, Inc. | 4.07% | 4,833,527 |
| The Vanguard Group, Inc. | 3.48% | 4,128,830 |
Who owns VXRT?
Top 10 Owners of Vaxart Inc
| Stockholder | Stake | Shares owned |
|---|---|---|
| BlackRock Fund Advisors | 5.87% | 7,369,160 |
| The Vanguard Group, Inc. | 4.51% | 5,661,340 |
| Geode Capital Management LLC | 1.68% | 2,112,241 |
| Northern Trust Investments, Inc.(… | 0.96% | 1,207,900 |
What VGX 3100?
VGX-3100 is an immunotherapy that targets human papillomavirus (HPV) 16 and 18 and is being studied to treat HPV-related precancerous lesions and the HPV infection that causes these lesions.
What is inovio Cellectra?
PROPRIETARY SMART DEVICES (CELLECTRA®) INOVIO’s DNA medicines deliver optimized plasmids directly into cells intramuscularly or intradermally using one of INOVIO’s proprietary hand-held CELLECTRA® smart devices.
What is the Inovio Pharmaceuticals 52-week low stock price?
The Inovio Pharmaceuticals 52-week low stock price is 5.81, which is 28.6% below the current share price. The average Inovio Pharmaceuticals stock price for the last 52 weeks is 9.83.
What is Inovio technology?
The Inovio technology is based on inserting engineered DNA into cells, where it becomes transcribed into mRNA and translated into proteins. The proteins encoded by the DNA elicit immune response to antigens from cancers and viruses, by stimulating the production of T cells and antibodies that aid recovery.
What is the Inovio covid-19 vaccine?
Inovio COVID-19 vaccine is a COVID-19 vaccine candidate developed by Inovio Pharmaceuticals . In February 2020 after receiving details of the genetic sequence of the coronavirus, Inovio announced that it had produced a preclinical DNA-based vaccine as a potential therapy for COVID-19.
What is Inovio’s CELLECTRA?
To facilitate use of its potential products, Inovio manufactures a proprietary injection device, called “Cellectra”, which the company describes as providing a “brief electrical pulse to reversibly open small pores in the cell to allow the plasmids to enter, overcoming a key limitation of other DNA and other nucleic acid approaches, such as mRNA .”
